Facilitators and barriers for performing comprehensive medication reviews and follow-up by multiprofessional teams in older hospitalised patients. by Kempen, Thomas Gerardus Hendrik et al.
CLINICAL TRIAL
Facilitators and barriers for performing comprehensive medication
reviews and follow-up by multiprofessional teams in older
hospitalised patients
Thomas Gerardus Hendrik Kempen1,2 & Amanda Kälvemark1 & Maria Sawires3 & Derek Stewart4 &
Ulrika Gillespie1,3
Received: 21 September 2019 /Accepted: 7 February 2020
# The Author(s) 2020
Abstract
Purpose There is a lack of knowledge about factors that influence the performance of comprehensive medication reviews
(CMRs) by multiprofessional teams in hospital practice. This study aimed to explore the facilitators and barriers for performing
CMRs and post-discharge follow-up in older hospitalised patients from the healthcare professional perspective.
Methods Physicians and ward-based pharmacists were recruited from an ongoing trial at four hospitals in Sweden. Semi-
structured interviews were conducted with 16 physicians and 7 pharmacists. Interview topics were working processes, resources,
competences, medication-related problems, intervention effects and collaboration. The interviews were audio-recorded, tran-
scribed verbatim and thematically analysed using the Consolidated Framework for Implementation Research (CFIR). Identified
subthemes were categorised as facilitators or barriers and grouped into overarching main themes.
Results In total, 21 facilitators and 25 barriers were identified across all CFIR domains and grouped in 6 main themes: (a) CMRs
and follow-up are needed, but not in all patients; (b) there is a general belief in positive effects; (c) lack of resources is an issue,
although the performance of CMRs may save time; (d) pharmacists’ knowledge and skills are valuable, but they need more
clinical competence; (e) compatibility with hospital practice is challenging, and roles and responsibilities are unclear and (f)
personal contact at the ward is essential for physician-pharmacist collaboration.
Conclusion Multiple facilitators and barriers for performing CMRs and post-discharge follow-up in older hospitalised patients
exist. These factors should be addressed in future initiatives with similar interventions by multiprofessional teams to ensure
successful implementation and performance in hospital practice.
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Introduction
Mismanaged prescribing and inappropriate use of medications
among older people are a major cause of avoidable harm in
healthcare systems across the world [1–3]. Performing com-
prehensive medication reviews (CMRs), a structured critical
examination of a patient’s medications in relation to the pa-
tient’s conditions and preferences, aims to optimise treatment
benefit and minimise harm [4, 5]. There is evidence that
performing such reviews by a multiprofessional team includ-
ing a clinical pharmacist can improve medication prescribing
and increase appropriate use of medications [6–9]. However,
less is known about the effects on hard clinical endpoints,
justifying the need for high-quality randomised controlled tri-
als (RCTs) [10].
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To fulfil this need, the Medication Reviews Bridging
Heal thcare (MedBridge; www.cl inical t r ia ls .gov:
NCT02986425) trial is currently being performed at four
hospitals in Sweden [11]. This RCT aims to study the effects
of two interventions compared with usual care on older
patients’ health outcomes: (1) a CMR by a ward-based phar-
macist in collaboration with the physician and patient during
hospital stay; and (2) the same as the first intervention, with
the addition of a follow-up phone call by the pharmacist 2–
7 days and 1–2 months after hospital discharge, and a medi-
cation referral to the patient’s general practitioner (GP) upon
discharge if necessary.
Clinical trials of interventions comprising multiple compo-
nents which interact to produce change, like CMRs, are often
criticised because of the difficulty to explain the results with-
out examining the underlying processes and the context in
which the interventions were performed [12]. Process evalua-
tions alongside such RCTs are therefore highly recommended
[13]. Qualitative approaches, such as interviews and focus
groups, are often used within process evaluations to provide
detailed information about the implementation and perfor-
mance of the different intervention components [13]. This
information may help to understand why the intervention
was or was not effective, which can be used to inform policy
decisions and support implementation in daily practice.
Process evaluations and other research involving
multiprofessional collaboration including ward-based phar-
macists often make use of surveys to study the views of the
involved healthcare professionals [14–19]. These survey stud-
ies report that physicians and nurses generally are satisfied
with the collaboration with the pharmacists and that an in-
crease in the quality and safety of the patients’ medication
treatment is perceived. The few available studies with a more
in-depth qualitative approach conclude that pharmacists can
contribute with their pharmaceutical competences and add
value to the ward team, but that organisational problems, such
as an improper defined role of the pharmacist and limited
availability of pharmacist resources, pose challenges to the
implementation of multiprofessional interventions [20–24].
One of these studies explored the working relationships of
physicians, nurses and ward-based pharmacists in a rural hos-
pital in northern Sweden after the introduction of a clinical
pharmacy service including CMRs [24]. It is unclear to what
extent these findings are representative for other hospitals in
Sweden. A more in-depth understanding is needed to support
implementat ion of CMRs or similar services by
multiprofessional ward teams including pharmacists on a
wider scale and to ensure long-term sustainability.
We previously explored older patients’ experiences with,
and views on, hospital-initiated CMRs and follow-up calls by
ward-based pharmacists, as part of a process evaluation of the
MedBridge trial [25]. Older patients generally had positive
experiences and views. However, some factors, like the
unclear role of the pharmacist and problems with receiving
and retaining information, may negatively impact effective-
ness within the trial. In this second part of the process evalu-
ation, we aimed to explore the facilitators and barriers for
performing CMRs and post-discharge follow-up in older
hospitalised patients from the healthcare professional
perspective.
Methods
Study design and methodological approach
A qualitative design with semi-structured interviews was cho-
sen to gain rich accounts of the healthcare professionals’ per-
spectives.We have taken an interpretive approach as proposed
by Snape and Spencer [26]. That is, we accept that the reality
exists independently of individual subjective understanding,
but that it is only accessible to the researchers via the partic-
ipants’ interpretations. The Standards for Reporting
Qualitative Research (SRQR) [27] were used to design and
report the study.
Study context
This study was performed in the context of the MedBridge
trial, which takes place at in total eight wards within four
hospitals in Sweden: the hospitals in Enköping, Gävle,
Uppsala and Västerås [11]. The wards differ in terms of med-
ical specialty: geriatric, internal medicine, stroke, diabetes and
nephrology. At these wards, the performance of medication
reviews by a multiprofessional team including a pharmacist
was already established (in Enköping, Gävle and Uppsala) or
was implemented about 6 months prior to the start of the trial
(in Västerås). The performance of follow-up phone calls and
use of medication referrals by pharmacists were introduced
and tested approximately 1 to 3 months before the trial started.
The pharmacists working at these wards had either completed
a full-time 1-year postgraduate programme in clinical pharma-
cy, or they had completed undergraduate courses in clinical
pharmacy and advanced pharmacotherapy. All patients aged
65 years or older who were admitted to one of the wards were
asked for informed consent to participate in the MedBridge
trial. Patients were excluded if they were in a palliative stage,
had been subject to a medication review within the last
30 days, resided in another than the hospital’s region or were
admitted for only 1 day. During admission, patients received
one of the study interventions or usual care (Fig.1). In total,
2644 patients were included in the MedBridge trial between
February 2017 and October 2018. Quantitative results on pri-
mary and secondary outcome measures are expected in mid-
2020.
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Sampling and recruitment
A purposive sampling approach [28] was used to identify
facilitators and barriers that cut across a variety of individuals.
In this approach, physicians and pharmacists that had directly
been involved in performing the CMRs in the MedBridge trial
(intervention 1 or 2) were recruited. We started in Uppsala
one month after the start of the trial and aimed to recruit at
least eight physicians with different degrees of medical train-
ing and positions (at least one consultant, one specialist in
training and one junior doctor from both wards) and all four
pharmacists. Potential participants were identified by the tri-
al’s local project leader and approached by the researcher who
would be conducting the interviews. With those responding
positively, a mutually convenient time and place for interview
was arranged.
After conducting the interviews and initial analysis in
Uppsala, we searched for deviant cases within the other three
hospitals: physicians who had expressed scepticism towards
collaboration with pharmacists; pharmacists with relatively
short and long working experience and pharmacists who had
expressed difficulties with performing the interventions
throughout theMedBridge trial. An audit trail was kept during
recruitment and data analysis.
Data generation
A discussion guide in Swedish was developed in relation
to the intervention components within the MedBridge trial
[11] and informed by the concepts of interprofessional
collaboration by D’Amour et al. [29]. The topics were
working processes, resources, competences, medication-
related problems, intervention effects and collaboration
(Appendix 1a). Within the interviews, the discussion
topics were fixed, whereas the order and exact formula-
tion of the questions were flexible. The interviews in
Uppsala were performed by a researcher (MS) who was
in the final year of the pharmacy programme and was
familiar with the trial’s interventions. The researcher did
not have previous professional relationships with the par-
ticipants. The interviews were conducted in March and
April 2017 and lasted between 15 to 40 min. The same
researcher who performed the interviews (MS) audio-
recorded and transcribed the interviews.
For the additional interviews, the order of the topics in the
discussion guide was changed and questions were added and
reformulated (Appendix 1b). The interviews in Enköping,
Gävle and Västerås were performed by a researcher (AK) with
a nursing background, who was working as a research assis-
tant for the MedBridge trial in Uppsala. The researcher was
trained in qualitative interviewing and had little to no profes-
sional relationship with the participants. Participants were en-
couraged to be frank and talk freely. Interviews were held
between May and October 2018, and lasted between 17 to
104 min (mean: 38 min). The interviews were audio-
recorded and transcribed verbatim by one researcher (AK)
and checked for transcribing accuracy by another researcher
(TK), who was the project coordinator in the MedBridge trial,
had a pharmacy background and was trained in qualitative
research.
Intervenon 1: 
CMR (n=924)
Intervenon 2: 
CMR with post-discharge follow-up (n=825)
Comprehensive medicaon review:
• A clinical pharmacist interviews the paent or carer to ensure a correct list of medicaons
and to idenfy any medicaon-related problems experienced by the paent;
• A structured, crical examinaon of the medicaons in relaon to informaon from the
paent and the medical record. The objecve is to reach an agreement between the
physician, pharmacist and paent about the medicaon treatment, opmising the impact
of medicaons and minimising the number of medicaon-related problems;
• Monitoring the effects of medicaon changes and a final check of the paent's medicaon
list and prescripons before discharge.
Referral to primary care if necessary:
• Electronic medicaon referral by the clinical pharmacist
to the paents’ GP with recommendaons on
treatment follow-up if deemed necessary.
Intervenons 
during 
hospitalisaon
Intervenons 
aer discharge
Usual care without a clinical 
pharmacist involved
Follow-up telephone calls:
• Telephone call aer 2-7 days by the clinical pharmacist
to the paent or carer to ensure that all informaon
has been understood correctly and to handle any
problems, concerns or quesons;
• Telephone call aer 1-2 months to the paent or carer.
Counselling is provided and any other acons are taken
if necessary.
Control: 
usual care (n=895)
Usual care 
without a clinical 
pharmacist 
involved
Study group
Fig. 1 Interventions within the
Medication Reviews Bridging
Healthcare (MedBridge) trial per
study group [11]. CMR, compre-
hensive medication review; GP,
general practitioner
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Data analysis
Thematic analysis was based on the framework approach
by Ritchie and Spencer [30] with the Consolidated
Framework for Implementation Research (CFIR) [31] to
structure the codes. The CFIR is a meta-theoretical frame-
work that has been used in healthcare research to guide
evaluation of implementation processes and help to ex-
plain outcomes in effectiveness studies [32]. The CFIR
consists of five domains, with each domain divided into
several constructs: intervention characteristics; outer set-
ting; inner setting; characteristics of individuals; and pro-
cess (Appendix 2a–c). Two researchers (MS and UG) in-
dependently analysed and coded the interview transcripts
from Uppsala. One of these researchers (UG) was project
leader in the MedBridge trial and had previous experience
in qualitative research. The results were then combined
into one CFIR-based matrix, and consensus was sought
on conflicting results. A third researcher (TK) was avail-
able to decide in case no consensus was found. The three
researchers (MS, UG and TK) then summarised and
interpreted the data within each CFIR construct to create
common subthemes in English, which were then
categorised as either facilitators or barriers (exemplified
in Appendix 2d). Subthemes that could be either a facil-
itator or a barrier were reformulated and divided into one
facilitator and one barrier. For the interviews at the other
three hospitals, two researchers (AK and TK) indepen-
dently coded the interview transcripts followed by the
same method as the interviews in Uppsala with a third
researcher (UG) involved in identification of subthemes
and categorisation into facilitators and barriers. These fa-
cilitators and barriers were then matched with those from
the interviews in Uppsala, resulting in one integrated
framework. As some facilitators and barriers were identi-
fied within more than one CFIR construct, these were
finally grouped into overarching main themes. Peer scru-
tiny of the sampling strategy, data generation and analysis
was performed by a researcher with extensive experience
in qualitative research within healthcare (DS). Research
trustworthiness and rigour [33] were addressed in diverse
ways throughout the research process (Appendix 3).
Results
Demographics of participants
Interviews were held with 16 physicians out of 22 physi-
cians who were invited for participation, and with all 7
pharmacists who were invited. Reasons for not participat-
ing were no time for an interview (n = 3), too little expe-
rience with the interventions (n = 1) and no response to
the invitation (n = 2). All four hospitals were represented
among both physicians and pharmacists (Appendix 4). All
positions, levels of training and other predefined charac-
teristics were present among the participants, with clinical
working experience ranging from a few weeks to over
25 years. Eight physicians were consultants, two were
specialists in training and six were junior doctors. Four
pharmacists held an additional postgraduate degree in
clinical pharmacy.
Facilitators and barriers
Facilitators and barriers were identified across all five
CFIR domains (Appendix 2a and 2b). All findings com-
bined (Appendix 2c) resulted in 21 facilitators and 25
barriers, grouped into 6 main themes (Table 1).
Frequent recurring factors and those interpreted as im-
portant by the researchers are discussed below and sup-
ported by illustrative quotes with the interview number
in parentheses (D1–16 for the physicians; P1–7 for the
pharmacists).
CMRs and follow-up are needed, but not in all patients
Physicians and pharmacists believed that the performance of
CMRs in older patients with multiple medications is needed.
However, not all patients need or appreciate a CMR, and
healthcare professionals would prefer to prioritise patients
with the highest need.
“You don’t need to go through all patients’ medication
lists, but especially the older multimorbid patients with
polypharmacy, there I think it’s great and I would like to
continue with this [performing CMRs] in the future, if I
have to be honest.” (D16)
Awareness of legislation and guidelines imposing the perfor-
mance of CMRs existed among pharmacists, and to less de-
gree, among physicians. Some physicians stated that a phar-
macist may not always be needed as they also conduct CMRs
themselves and that other medical specialists can be consulted
with medication-related questions.
“For example, if I’m uncertain about antibiotics […] I
talk to the infection specialist […] about adjusting dos-
age and such things.” (D14)
General belief in positive effects of CMRs and follow-up
There was a belief that CMRs and follow-up calls could
reduce “medication errors” (D11), increase “compliance”
(P2) and “patient safety” (D4) and “prevent readmissions”
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(D3), although the long-term effects on health outcomes
were questioned as well. Treatment proposals by pharma-
cists were “most often relevant” (D15), and the CMRs
became “more thorough” (D14) and of “higher quality”
(D12) if pharmacists were involved. Although medication
referrals and phone calls were considered useful interven-
tions, patients could become “stressed out” (P5) by the
phone calls, and there were doubts about the quality of
follow-up in primary care, which may reduce the inter-
ventions’ effectiveness.
Table 1 Facilitators and barriers for performing comprehensive
medication reviews and post-discharge follow-up byward-based pharma-
cists in older hospitalised patients grouped into six main themes. These
factors were derived from interviews with both physicians and pharma-
cists, if not stated otherwise
Facilitators Barriers
CMRs and follow-up are needed, but not in all patients
• Patients need and appreciate CMRsI–IV
• Awareness of legislation and guidelines on CMRs among HCPsII,IV
• Need for and willingness to take part in research among HCPsI,III,V
• Not all patients want, need or feasible for CMRI–III,V
• Pharmacist involvement not always necessaryI
• Little knowledge about evidence, legislation and guidelines on CMRs
among physiciansI,II
General belief in positive effects of CMRs and follow-up
• HCPs belief in positive effects of CMRsI–IV
• Pharmacist’s work is relevant and appreciated by physiciansI,III,IV
• CMR more thorough with pharmacist involvementI,III,IV
• Positive attitude among pharmacists towards referrals and phone
callsI–III,V (only derived from pharmacist interviews)
•Uncertainty among physicians about the long-term effects of CMRsI (only
derived from physician interviews)
• Insufficient quality of and communication about post-discharge follow-up
by primary careII,III
• Phone calls may disturb patientsII (only derived from pharmacist
interviews)
Lack of resources is an issue, although the performance of CMRs may save time
• CMR or pharmacist may save time and costsI,III
• Availability of shared electronic medical recordII,III
• Lack of time among HCPsI,III,V
• No time set for physician-pharmacist contactI,III,IV
• CMR takes time for both pharmacist and physicianI,III
• Phone calls and check upon discharge for all patients is not time
efficientI–V (only derived from pharmacist interviews)
• Electronic medical record is not complete, fully shared or user-friendlyII,III
Pharmacists’ knowledge and skills are valuable, but they need more clinical competence
• Knowledge about the interventions among HCPsI,IV,V
• Pharmacist is reliable and has broad pharmaceutical competenceI,III,IV
• Physicians cannot know everything about medicationsIV (only derived
from physician interviews)
• Positive change in physicians’ attitude and knowledgeIII,IV
• Pharmacist lacks or needs more clinical competenceI,III–V
• Lack of information or training about the interventions and working
process among HCPsIII–V
• Physicians’ competence may decreaseIV (only derived from physician
interviews)
Compatibility of CMRs with hospital practice is challenging, and roles and responsibilities of ward-based pharmacists are unclear
• CMR or pharmacist is well-adapted to hospital practiceI,III–V
• CMR or pharmacist does not interfere with existing work flowI,III,V
• Physician has main responsibilityII (only derived from physician
interviews)
• Hard to fit CMR in hospital practiceI,III,IV
• Primary care or others responsible and suited for CMRI,III,IV
• Pharmacist is not fully integrated in the ward teamIII
• Unclear role of the pharmacistI–V
• Pharmacist is dependent on the physicianII–IV
Personal contact at the ward is essential for physician-pharmacist collaboration
• Positive experience by physicians with pharmacist collaborationIII,IV
(only derived from physician interviews)
• Presence of pharmacist at the ward and availabilityIII
• Personal relationships between HCPsIII
• Pharmacist participates in medical rounds or meetingsI,III
• Pharmacist has support from other colleaguesIII (only derived from
pharmacist interviews)
• Pharmacist is not always present at the wardIII
• Limited contact between pharmacist and consultant physicianIII
• Physicians can feel criticised by the pharmacistIII (only derived from
physician interviews)
• Some physicians less inclined to listen to the pharmacistIII,IV
• Pharmacist notes in electronic medical record not always appreciatedI,III,V
• Frequent rotation of HCPs at the wardI,III
CMR comprehensive medication review, HCP healthcare professional
Identified within the CFIR domains [31]:
I Intervention characteristics
II Outer setting
III Inner setting
IV Characteristics of individuals
V Process
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“They [GPs] often accept our referrals, but then they are
under much pressure in primary care and a follow-up
visit may get forgotten, or it may take a long time until
the next visit.” (P1)
Lack of resources is an issue, although the performance
of CMRs may save time
Lack of time was an important barrier. Finding time for
physician-pharmacist contact, monitoring patients during hos-
pital stay and conducting follow-up calls could be “very hard”
(P7) and “stressful” (P4) for pharmacists. The performance of
CMRs by pharmacists could be time-saving for physicians by
supporting them in their work, but it could also increase their
workload when medication-related problems were identified
during hospital stay.
“Yes, it can take time […] but I think it saves more time
than what it takes, so it’s well-invested time.” (D16)
All pharmacists questioned the cost-effectiveness of
performing phone calls to all patients, as they felt that many
patients did not need or were not feasible for such follow-up.
“I think that the way we’ve worked in the study, calling
every patient, is a waste of time. I don’t think that we
make best use our competence in that way.” (P5)
Shared electronic record was a major facilitator for communi-
cation between physicians and pharmacist and, when avail-
able, between hospitals and primary care practices. The phar-
macists’ notes could however contain “too much text” (D13),
and in-person discussion of treatment proposals was preferred
over written communication, because “patients read it all […]
and it gets confusing” (D14).
Pharmacists’ knowledge and skills are valuable, but they
need more clinical competence
Pharmacists were seen as reliable professionals with “broad
pharmaceutical competence” (D15), “complementary” (D9)
to the physicians’. Their clinical competence could however
be improved to provide more clinically relevant input.
“For example, to change antihypertensive medication
because of one high blood pressure measurement. Just
because the patient is acutely ill today, does not mean
that this treatment needs to be changed in the long term.”
(D14)
Collaboration with the pharmacist could increase the physi-
cians’medication-related knowledge, but there was also a risk
that physicians would “lose some feeling for it, because they
have become accustomed to using pharmacists” (D8).
Physicians were generally uninformed about the CMR proce-
dures and about which patients would receive a CMR and
post-discharge follow-up. Pharmacists were better informed,
but some expressed a lack of training and instructions on how
and when to send medication referrals, and how to conduct
monitoring and follow-up.
“It feels like we developed some kind of ad hoc method.
Right before we started [the trial] it was like: Call the
patient and take it from there, just reconcile and make
sure the patient has the medications and understood ev-
erything.” (P5)
Compatibility of CMRs with hospital practice is challenging,
and roles and responsibilities of ward-based pharmacists are
unclear
Pharmacists had to adapt and fit the CMRs into the existing
workflow and often only address medication-related issues
that were relevant during hospital stay. It seemed that pharma-
cists had succeeded doing this, but it was harder at wards
where pharmacists had recently been introduced.
“It is important to understand that not everything is rel-
evant to address, and that some things don’t have to be
changed right now. You just focus on what’s most rele-
vant to the patient.” (P1)
Some physicians felt that their responsibility was to focus on
the cause of admission instead of assessing the patient’s full
medication treatment, and that “primary care practices may be
better suited” (D9) for performing CMRs. Pharmacists
questioned whether they were responsible for the patient’s
medication treatment when problems arose during the phone
call 1–2 months after discharge. Pharmacists were not fully
integrated in the ward team, and their roles, responsibilities
and way of working were often not clearly defined. These
were major barriers causing “double workload” (P6) and
“frustration” (D7). The pharmacists’ dependency on physi-
cians hindered efficiency and “the right to make changes to
the medication list” (P7) was proposed to overcome this
barrier.
Personal contact at the ward is essential
for physician-pharmacist collaboration
The physician-pharmacist collaboration was generally posi-
tive. Pharmacists were easily accessible. Their presence at
medical ward rounds and frequent in-person contact were val-
ued, but this was not common practice at all wards.
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“I have been on medical rounds in which the pharma-
cists did not participate, but came later, and that did not
work so well.” (D3)
Building personal relationships was an important facilitator,
but frequent staff rotations, pharmacists not always being
present at the ward and difficulties reaching the consultant
physician, acted as barriers.
“There’s a lot of staff rotation, […] it takes time for them
to get integrated in the work method, and to know what
they can expect from us and what we can expect of
them.” (P4)
Some physicians were more sceptical and less inclined to
listen to the pharmacist, but this seemed to improve over time.
Junior doctors could sometimes become “a messenger be-
tween the pharmacist and consultant physician” (D10), in-
creasing the risk of miscommunication.
Discussion
This study identified multiple facilitators and barriers,
grouped in six main themes, for performing CMRs and post-
discharge follow-up by multiprofessional teams in older
hospitalised patients. These factors were derived from inter-
views with physicians and pharmacists, as part of a process
evaluation of the MedBridge trial [11].
Physicians and pharmacists believed that older patients
need and may benefit from CMRs and post-discharge fol-
low-up. However, due to the design of the MedBridge trial,
these interventions were also conducted in patients who might
not needed, wanted or were feasible for these interventions,
which may have lowered effectiveness and efficiency.
Availability of time and resources, including shared electronic
medical records, was deemed essential. The CFIR acknowl-
edges the importance of accounting for patient characteristics
and needs, prioritisation and the availability of resources [31].
Validated tools to identify patients at high risk for medication-
related problems could be used to make more efficient use of
available resources [34]. These tools may require self-
assessment by the patient [35] or algorithm-based screening
of the electronic medical record [36, 37]. Our findings seem
consistent with those from qualitative research on CMRs and
related interventions by multiprofessional ward teams in other
countries and regions [20, 21, 24, 38, 39]. Physicians think
that pharmacists are reliable and add knowledge to the team
[20, 21, 24]; they perceive positive contribution to the shared
goal to improve patient care and safety [21, 38, 39], and pres-
ence by pharmacists at the ward is essential to build profes-
sional relationships [21, 24]. Theories on interprofessional
collaboration and the CFIR emphasise the importance of these
facilitators [31, 40]. Although the pharmacists’ knowledge
and skills were valued, there was a need for more clinical
competence, which is a known area for improvement in phar-
macy education worldwide [41, 42]. Pharmacists mentioned
being dependent on physicians during the CMR process to
make changes to patients’ medication treatment. Physicians
also conducted CMRs without pharmacist involvement, but
these were less thoroughly performed. Little to no dependency
on pharmacists was identified among physicians, whereas in-
terdependency is an important element of successful collabo-
ration [43]. Unlike in the UK, pharmacists in Sweden do not
have prescribing rights. Providing these rights and appropriate
training to pharmacists may therefore be an opportunity to
make the CMR process more efficient and improve collabo-
ration [44].
Flexibility to ensure compatibility with hospital practice
was identified as a facilitator in this study. However, it was
questioned whether hospital is the most suitable setting to
conduct CMRs. Patients may be too ill and not willing to be
involved in the CMR process during hospitalisation [25]. Our
findings also show that specialist physicians at internal med-
icine wards may not consider CMRs their responsibility and
refer to primary care. GPsmay on the other hand not be certain
about whose responsibility it is to conduct CMRs either [45].
Multiprofessional collaboration can lead to an improved
understanding of the pharmacist’s role in the team [24, 38].
In our study, different perspectives on roles and responsibili-
ties of the pharmacist seemed however to persist. Clarification
of tasks and roles is key to successful collaboration and can
improve implementation climate [31, 43]. Failure to clarify
roles in our trial may be reflected in pharmacists not being
perceived as an integrated part of the ward team and physi-
cians not being well-informed about the trial’s interventions
and working processes. Consistent with previous research [20,
21, 24, 38, 39], we identified more barriers related to team-
work and collaboration, like pharmacists not always being
present at the ward, frequent staff rotations and a lack of time
for physician-pharmacist contact. Having pharmacists struc-
turally participate in medical ward rounds may facilitate col-
laboration. These findings also corroborate our previous re-
search on patient experience with and views on the interven-
tions in the MedBridge trial [25]. Patients valued physician-
pharmacist collaboration and the pharmacists’ knowledge and
competence, but a lack of understanding about the CMR pro-
cess and role of the pharmacist may decrease the interven-
tions’ effectiveness.
Limitations of the study
Despite multiple measures taken to ensure research trustwor-
thiness [33], some limitations to this study exist. Data satura-
tion [46] was not formally assessed, and the interviews in
Uppsala were performed during the first and second period
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(out of six) of the MedBridge trial; hence, relevant data could
have beenmissed. Four out of five researchers had a pharmacy
background, which may have led to findings being relatively
more positive towards pharmacists. Finally, inherent to qual-
itative research, the degree of potential influence by the iden-
tified facilitators and barriers on the effectiveness of the trial
interventions was not measured. We do therefore not know
whether the facilitators outweigh the barriers.
Research and practice implications
This study identified facilitators and barriers which provide
possible explanations for why the CMRs and post-discharge
follow-up in the MedBridge trial may or may not have been
effective. Future initiatives with similar interventions includ-
ing ward-based collaboration between physicians and phar-
macists could address these factors to ensure successful im-
plementation and performance in hospital practice. Our find-
ings emphasise that there is a belief in the need for and ben-
efits of CMRs and post-discharge follow-up in older patients.
These interventions should however be adapted to fit hospital
practice, perhaps only focusing on medications related to the
cause of admission, and tailored to the patients’ individual
needs and preferences. Appropriate allocation of time and
resources is important, but simply introducing pharmacists
to a multiprofessional ward team does not automatically lead
to integration. Roles, tasks and responsibilities of the ward
team and others involved in patient care in relation to CMRs
and post-discharge follow-up should jointly be decided upon.
Conclusion
Multiple facilitators and barriers for performing CMRs and
post-discharge follow-up in older hospitalised patients exist.
This study promotes a better understanding of how to address
these factors in future initiatives with similar interventions by
multiprofessional ward teams, including clinical pharmacists,
to ensure successful implementation and performance in hos-
pital practice.
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